9 Meters Biopharma, Inc. (OTCPK: NMTR.Q)
Health Care · Pharmaceuticals · US
$0.00
— today · 0.0% 1Y
9 Meters Biopharma, Inc. (OTCPK: NMTR.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $14.00 and employs 10 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores 9 Meters Biopharma, Inc. across four factors: quality 19/100. Its strongest factor is quality.
NMTR.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.53
- Dividend yield
- —
- Beta (5Y)
- 11.21
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 14.46M
- Employees
- 10
- Next earnings
- —
About 9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
- ISIN
- US6544052086
- Listed since
- Jul 11, 2016
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,231.78 | -0.15% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $272.81 | -0.12% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF371.90 | -0.51% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.29 | -1.18% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.